## ğŸ“ Executive Summary: HE 9 - Economic Evaluation I

The lecture **HE 9 - Economic Evaluation I**, delivered on **May 22, 2025**, as part of the **MQB7014: Health Economics** module in the **Master of Public Health (MPH)** programme at the University of Malaya, introduces the foundational principles of **economic evaluation** in healthcare. Presented by **Dr. Ainol Haniza Kherul Anuwar** with credit to **Prof. Dr. Maznah Dahlui**, the lecture emphasizes the role of economic evaluation in addressing **scarcity**, guiding **resource allocation**, and ensuring **value for money** in health systems, particularly in Malaysiaâ€™s context. Through a structured exploration of definitions, types, economic concepts, perspectives, and timing, the lecture equips students to make **evidence-based**, **equitable**, and **efficient** decisions that align with **Universal Health Coverage (UHC)** and **Health Technology Assessment (HTA)** goals. Below is a concise summary of the key points and terminologies introduced, designed to provide a clear overview for public health professionals and policymakers ğŸŒ.

### ğŸ“š Overview of Economic Evaluation ğŸ©º

**Economic evaluation** is a cornerstone of health economics, defined as _â€œa comparative analysis of alternative courses of action in terms of both their costs and consequencesâ€_ (Drummond et al., 2005). It addresses the **fundamental challenge of scarcity**â€”where **limited resources** (money, staff, facilities) cannot meet **infinite health needs**â€”by providing a systematic framework to assess **value for money**. The lecture highlights its applications in Malaysia, such as prioritizing **high-impact programs** like **Peka B40** and **Vaccination Programmes**, and supporting **HTA** through **MaHTAS**. Key concepts include **opportunity cost**, **efficiency**, and **marginal analysis**, with evaluations tailored to perspectives like **societal** or **patient** to ensure **transparency** and **equity**.

### ğŸ” Key Points from the Lecture ğŸ“‹

The lecture is structured into 11 sections, each addressing critical aspects of economic evaluation:

- **Introduction to Economic Evaluation**: Defines economic evaluation as a tool to compare **costs** and **consequences**, emphasizing its role in addressing **scarcity** and guidingéµ

System: It looks like the input was cut off mid-sentence. Based on the provided instructions and the lecture content for **HE 9 - Economic Evaluation I**, Iâ€™ll complete the executive summary, ensuring **full fidelity** to the original content, incorporating all key points and terminologies from Sections 1â€“11, and adhering to the formatting requirements (clear headings, bold highlights, bullet points, tables, emojis, LaTeX for equations, and no dash dividers). The response will be structured for Obsidian Markdown compatibility, with tables using consistent pipes (|) and dashes (-), and will include a dedicated section for **key terminologies** introduced in the lecture. If further elaboration is needed, Iâ€™ll indicate continuation options.

---

## ğŸ“ Executive Summary

The lecture **HE 9 - Economic Evaluation I**, delivered on **May 22, 2025**, as part of the **MQB7014: Health Economics** module in the **Master of Public Health (MPH)** programme at the University of Malaya, introduces the foundational principles of **economic evaluation** in healthcare. Presented by **Dr. Ainol Haniza Kherul Anuwar** with credit to **Prof. Dr. Maznah Dahlui**, the lecture emphasizes the role of economic evaluation in addressing **scarcity**, guiding **resource allocation**, and ensuring **value for money** in health systems, particularly in Malaysiaâ€™s context. Through a structured exploration of definitions, types, economic concepts, perspectives, and timing, the lecture equips students to make **evidence-based**, **equitable**, and **efficient** decisions that align with **Universal Health Coverage (UHC)** and **Health Technology Assessment (HTA)** goals. Below is a concise summary of the key points and terminologies introduced, designed to provide a clear overview for public health professionals and policymakers ğŸŒ.

### ğŸ“š Overview of Economic Evaluation ğŸ©º

**Economic evaluation** is a cornerstone of health economics, defined as _â€œa comparative analysis of alternative courses of action in terms of both their costs and consequencesâ€_ (Drummond et al., 2005). It addresses the **fundamental challenge of scarcity**â€”where **limited resources** (money, staff, facilities) cannot meet **infinite health needs**â€”by providing a systematic framework to assess **value for money**. The lecture highlights its applications in Malaysia, such as prioritizing **high-impact programs** like **Peka B40** and **Vaccination Programmes**, and supporting **HTA** through **MaHTAS**. Key concepts include **opportunity cost**, **efficiency**, and **marginal analysis**, with evaluations tailored to perspectives like **societal** or **patient** to ensure **transparency** and **equity** in decision-making.

### ğŸ” Key Points from the Lecture ğŸ“‹

The lecture is structured into 11 sections, each addressing critical aspects of **economic evaluation**:

- **Introduction to Economic Evaluation**: Introduces **economic evaluation** as a **comparative**, **systematic** tool to assess **value for money**, guiding **resource allocation** in Malaysiaâ€™s health system to address **scarcity** and support **UHC** goals ğŸ©º.
- **Challenge of Scarcity in Healthcare**: Highlights **scarcity** as the driver of **trade-offs**, where **limited resources** force **prioritization** (e.g., funding **cancer screening** vs. **ICU beds**). Traditional **gut feelings** are inadequate, necessitating **rational frameworks** like economic evaluation ğŸŒ.
- **Defining Economic Evaluation**: Defines it as a **comparative analysis** of **costs** and **consequences**, answering _â€œIs the added benefit worth the additional cost?â€_ It supports **efficient allocation**, prioritizing **high-value interventions** (e.g., comparing treatments costing RM 10,000 vs. RM 14,000 for 3 vs. 4 life years) ğŸ’°.
- **Understanding Costs and Consequences**: Outlines **costs** (direct medical, non-medical, indirect, intangible) and **consequences** (clinical, preference-weighted, economic), which must be **identified**, **measured**, and **valued** based on **perspective** ğŸ“ˆ.
- **Relevance to Health Systems**: Emphasizes economic evaluationâ€™s role in addressing **limited budgets** and **rising demand**, ensuring **transparency**, **accountability**, and **fair resource use** in Malaysiaâ€™s **HTA** (via **MaHTAS**), **formulary listing** (**MyHEALTH**, **MyHD**), and **UHC** initiatives ğŸŒ.
- **Types of Economic Evaluation**: Details four typesâ€”**CMA** (same outcomes, cost-focused), **CEA** (natural units, e.g., life years), **CUA** (QALYs/DALYs), and **CBA** (monetary outcomes)â€”each suited to specific contexts, with **CUA** preferred for **HTA** in Malaysia ğŸ“Š.
- **Partial vs. Full Economic Evaluation**: Contrasts **partial evaluations** (single intervention, no comparator) with **full evaluations** (comparing alternatives), noting that **full evaluations** provide a **robust basis** for decision-making âš–ï¸.
- **Core Economic Concepts**: Explores **opportunity cost** (trade-offs), **scarcity** (limited resources), **efficiency** (technical and allocative), and **marginal analysis** (incremental cost-benefit via **ICER**), underpinning **value-driven** decisions ğŸ§ .
- **Perspective in Economic Evaluation**: Defines **perspective** as determining **whose costs** and **benefits** are included (societal, health system, payer, patient), with examples like **breast cancer therapy** yielding different conclusions per perspective ğŸ‘ï¸.
- **Timing and Situations for Economic Evaluation**: Identifies when to conduct evaluations (e.g., new interventions, scaling programs, budget allocation) and when to avoid them (e.g., uncertain outcomes), emphasizing alignment with **planning cycles** â°.
- **Key Takeaways**: Summarizes economic evaluation as a tool for **wise decisions** in **scarcity**, supporting **equity**, **efficiency**, and **sustainability** in Malaysiaâ€™s health system and beyond ğŸŒŸ.

### ğŸ“– Key Terminologies Introduced ğŸ§ 

The lecture introduces several **key terminologies** critical to understanding **economic evaluation**:

- **Economic Evaluation**: _A comparative analysis of alternative courses of action in terms of both their costs and consequences_ (Drummond et al., 2005). It assesses **value for money** to guide resource allocation ğŸ’°.
- **Scarcity**: _Resources (money, staff, time, technology) are limited, but health needs are unlimited_, necessitating **prioritization** and **trade-offs** ğŸŒ.
- **Opportunity Cost**: _The value of the next best alternative forgone when a decision is made_, highlighting trade-offs (e.g., funding **vaccinations** vs. **ICU beds**) ğŸ’¸.
- **Costs**: _The value of resources used in an intervention_, including:
    - **Direct Medical Costs**: Expenses like **hospital stays**, **medications**, **staff time** ğŸ©º.
    - **Direct Non-Medical Costs**: Costs like **transport**, **caregiving** ğŸš—.
    - **Indirect Costs**: **Productivity losses** due to illness or treatment ğŸ’¼.
    - **Intangible Costs**: Non-monetized costs like **pain**, **anxiety** ğŸ˜Ÿ.
- **Consequences**: _The outcomes or effects of an intervention_, including:
    - **Clinical**: Outcomes like **infections prevented**, **life years gained** ğŸ“ˆ.
    - **Preference-Weighted**: Metrics like **QALYs** (Quality-Adjusted Life Years) or **DALYs** (Disability-Adjusted Life Years) âš–ï¸.
    - **Economic**: **Monetized outcomes** in **CBA** ğŸ’µ.
- **Value for Money**: The balance of **costs** and **health benefits**, ensuring resources deliver maximum impact ğŸ“Š.
- **Cost-Minimization Analysis (CMA)**: Compares costs when outcomes are identical, choosing the cheapest option (e.g., bioequivalent drugs) ğŸ’°.
- **Cost-Effectiveness Analysis (CEA)**: Measures outcomes in **natural units** (e.g., life years), using the **ICER** (Incremental Cost-Effectiveness Ratio, $\text{ICER} = \frac{\Delta \text{Cost}}{\Delta \text{Effectiveness}}$) to assess cost per outcome (e.g., RM 50,000/life year) ğŸ“ˆ.
- **Cost-Utility Analysis (CUA)**: Uses **QALYs** or **DALYs** to capture **quantity** and **quality of life**, common in **HTA** (e.g., RM 100,000/QALY) âš–ï¸.
- **Cost-Benefit Analysis (CBA)**: Converts outcomes to **monetary value**, comparing benefits to costs (e.g., workplace health ROI) ğŸ’µ.
- **Partial Evaluation**: A **cost-outcome study** of a single intervention without a comparator, limiting **relative value** assessment ğŸ”.
- **Full Economic Evaluation**: Compares **two or more interventions** for **robust decision-making** (e.g., vaccine vs. standard care) âš–ï¸.
- **Efficiency**: _Achieving maximum benefit from available resources_, via:
    - **Technical Efficiency**: Lowest cost for a given output (e.g., generic drugs) ğŸ’Š.
    - **Allocative Efficiency**: Maximizing **population health** (e.g., prioritizing vaccinations) ğŸŒ.
- **Marginal Analysis**: Examines **incremental cost** and **benefit** of small changes, using **ICER** to optimize decisions ğŸ§ .
- **Perspective**: Defines **whose costs and benefits** are included (e.g., **societal**, **health system**, **payer**, **patient**), shaping evaluation outcomes ğŸ‘ï¸.
- **Health Technology Assessment (HTA)**: Evaluates **new drugs** or **devices** for cost-effectiveness, used by **MaHTAS** in Malaysia ğŸ§ª.
- **Universal Health Coverage (UHC)**: Ensures **equitable access** to healthcare, supported by economic evaluation ğŸŒ.

### ğŸŒŸ Why This Matters ğŸ‡²ğŸ‡¾

The lecture underscores **economic evaluation** as a tool for **wise decisions** in the face of **scarcity**, ensuring **equity**, **efficiency**, and **sustainability** in Malaysiaâ€™s health system. By applying concepts like **ICER**, **QALYs**, and **perspective**, professionals can prioritize **high-impact programs** (e.g., **Peka B40**, **Vaccination Programmes**) and support **HTA** via **MaHTAS** and **UHC** goals. Globally, these principles transform **limited resources** into **maximum health impact**, empowering students to drive **evidence-based policymaking** ğŸŒŸ.

|**Key Takeaway**|**Why It Matters**|
|---|---|
|**Economic evaluation** assesses **value for money**|Guides **efficient** resource allocation|
|**Types** (CMA, CEA, CUA, CBA) suit diverse contexts|Aligns with **HTA** and **UHC** goals|
|**Perspective** and **timing** shape outcomes|Ensures **equitable** and **relevant** decisions|